Syncom Formulations (India) Ltd
Established in the year 1995, Syncom Formulations is a global pharmaceutical company that manufactures and markets a broad range of healthcare products. The company is a generic pharmaceutical player operating in more than 15 countries worldwide having more than 400 products registered.[1]
- Market Cap ₹ 1,927 Cr.
- Current Price ₹ 20.5
- High / Low ₹ 23.1 / 7.25
- Stock P/E 71.3
- Book Value ₹ 3.05
- Dividend Yield 0.00 %
- ROCE 10.4 %
- ROE 8.72 %
- Face Value ₹ 1.00
Pros
Cons
- Stock is trading at 6.73 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of 6.70% over past five years.
- Company has a low return on equity of 8.98% over last 3 years.
- Earnings include an other income of Rs.12.5 Cr.
- Working capital days have increased from 169 days to 242 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
115 | 151 | 173 | 184 | 185 | 159 | 187 | 206 | 245 | 216 | 222 | 258 | 286 | |
104 | 135 | 155 | 167 | 168 | 147 | 175 | 189 | 207 | 196 | 202 | 231 | 254 | |
Operating Profit | 11 | 16 | 18 | 17 | 16 | 12 | 12 | 17 | 38 | 20 | 20 | 28 | 32 |
OPM % | 9% | 11% | 11% | 9% | 9% | 7% | 6% | 8% | 16% | 9% | 9% | 11% | 11% |
1 | 1 | 1 | 3 | 3 | 4 | 5 | 5 | 7 | 12 | 15 | 13 | 13 | |
Interest | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 3 | 4 | 4 |
Depreciation | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 5 | 5 | 5 |
Profit before tax | 8 | 14 | 16 | 16 | 16 | 12 | 13 | 17 | 41 | 26 | 27 | 32 | 36 |
Tax % | 33% | 33% | 38% | 36% | 33% | 28% | 12% | 18% | 28% | 24% | 24% | 26% | |
6 | 9 | 10 | 10 | 11 | 9 | 11 | 14 | 29 | 20 | 20 | 24 | 27 | |
EPS in Rs | 0.07 | 0.12 | 0.13 | 0.13 | 0.14 | 0.11 | 0.14 | 0.18 | 0.37 | 0.23 | 0.21 | 0.25 | 0.29 |
Dividend Payout % | 24% | 17% | 16% | 15% | 15% | 0% | 0% | 0% | 0% | 131% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 6% |
5 Years: | 7% |
3 Years: | 2% |
TTM: | 23% |
Compounded Profit Growth | |
---|---|
10 Years: | 10% |
5 Years: | 16% |
3 Years: | -7% |
TTM: | 32% |
Stock Price CAGR | |
---|---|
10 Years: | 15% |
5 Years: | 93% |
3 Years: | 47% |
1 Year: | 137% |
Return on Equity | |
---|---|
10 Years: | 10% |
5 Years: | 11% |
3 Years: | 9% |
Last Year: | 9% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 22 | 78 | 78 | 78 | 78 | 78 | 78 | 78 | 79 | 86 | 94 | 94 |
Reserves | 65 | 17 | 22 | 31 | 36 | 44 | 55 | 68 | 99 | 131 | 162 | 192 |
2 | 3 | 6 | 6 | 12 | 12 | 9 | 2 | 62 | 58 | 83 | 72 | |
33 | 42 | 31 | 61 | 48 | 37 | 32 | 33 | 52 | 33 | 38 | 33 | |
Total Liabilities | 123 | 140 | 138 | 175 | 175 | 171 | 173 | 181 | 292 | 308 | 377 | 392 |
50 | 50 | 46 | 46 | 85 | 89 | 89 | 93 | 91 | 94 | 91 | 120 | |
CWIP | 0 | 0 | 0 | 5 | 0 | 1 | 0 | 0 | 0 | 6 | 26 | 0 |
Investments | 7 | 9 | 6 | 23 | 1 | 2 | 2 | 1 | 11 | 43 | 64 | 66 |
66 | 80 | 85 | 101 | 89 | 79 | 83 | 87 | 189 | 165 | 196 | 206 | |
Total Assets | 123 | 140 | 138 | 175 | 175 | 171 | 173 | 181 | 292 | 308 | 377 | 392 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
6 | 0 | 0 | 24 | 17 | -2 | 4 | 6 | -2 | 16 | 10 | -6 | |
-0 | 0 | 1 | -23 | -8 | -2 | 2 | 2 | -75 | -27 | -45 | 84 | |
-6 | 0 | 1 | -2 | -2 | -2 | -0 | -7 | 72 | 8 | 35 | -15 | |
Net Cash Flow | -1 | 0 | 2 | -1 | 6 | -6 | 7 | 1 | -5 | -2 | 1 | 63 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 92 | 71 | 66 | 91 | 91 | 87 | 81 | 77 | 112 | 114 | 124 | 132 |
Inventory Days | 29 | 36 | 34 | 43 | 29 | 37 | 37 | 39 | 51 | 51 | 53 | 49 |
Days Payable | 91 | 105 | 63 | 130 | 92 | 75 | 57 | 49 | 66 | 36 | 52 | 33 |
Cash Conversion Cycle | 29 | 1 | 37 | 4 | 27 | 49 | 61 | 67 | 96 | 129 | 124 | 148 |
Working Capital Days | 101 | 83 | 97 | 51 | 70 | 103 | 90 | 92 | 121 | 131 | 133 | 242 |
ROCE % | 10% | 15% | 16% | 15% | 14% | 9% | 9% | 12% | 21% | 11% | 10% | 10% |
Documents
Announcements
-
Clarification sought from Syncom Formulations India Ltd
24h - Exchange has sought clarification from Syncom Formulations India Ltd on August 27, 2024 with reference to significant movement in price, in order to ensure that …
- Clarification On Increase In Volume Of The Security Of The Company 24h
-
Clarification On Increase In Volume Of The Security Of The Company.
22 Aug - The significant change in the price might be purely due to market conditions and absolutely market driven.
-
Clarification sought from Syncom Formulations India Ltd
22 Aug - Exchange has sought clarification from Syncom Formulations India Ltd on August 22, 2024, with reference to Movement in Volume.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
13 Aug - Newspaper Publication for the financials of quarter ended 30.06.2024
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Business Overview
The company manufactures and markets 500+ pharmaceutical formulations products in various dosage forms like Tablets, Capsules, Liquids Orals, Liquid Vials and Ampoule Injections & Dry Vial injections, Dry Syrups, Ointments and Inhalers. It is also involved in trading commodities and rental of properties. [1]